dc.contributor.author | Park, Michael K. | eng |
dc.contributor.author | Smith, Peter C. | eng |
dc.contributor.author | Wanserski, Gerri R. | eng |
dc.date.issued | 2009 | eng |
dc.description.abstract | Aspirin in a daily dose of 160 to 300 mg initiated within 48 hours of symptom onset results in a net decrease in morbidity and mortality caused by acute ischemic stroke (Strength of Recommendation [SOR]: A, based on a systematic review), regardless of the availability of computed tomography (CT). (SOR: A, based on a meta-analysis). Aspirin is as effective as anticoagulants in this regard and causes less harm (SOR: A, based on a systematic review), but it should not be used in patients receiving thrombolytic therapy. (SOR: B, based on one randomized controlled trial [RCT]). | eng |
dc.identifier.uri | http://hdl.handle.net/10355/3985 | eng |
dc.language | English | eng |
dc.publisher | Family Physicians Inquiries Network | eng |
dc.relation.ispartofcollection | Clinical Inquiries, 2009 (MU) | eng |
dc.relation.ispartofcommunity | University of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network | eng |
dc.relation.ispartofseries | American family physician, 79, no. 03 (February 2009) | eng |
dc.rights | OpenAccess. | eng |
dc.rights.license | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. | eng |
dc.subject | atherothrombotic disease | eng |
dc.subject | International Stroke Trial (IST) | eng |
dc.subject | Chinese Acute Stroke Trial (CAST) | eng |
dc.subject | hemorrhagic stroke | eng |
dc.subject.lcsh | Cerebrovascular disease -- Treatment | eng |
dc.subject.lcsh | Aspirin -- Therapeutic use | eng |
dc.subject.lcsh | Cerebrovascular disease -- Prevention | eng |
dc.title | Aspirin in Patients with Acute Ischemic Stroke | eng |
dc.type | Article | eng |